Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study.

ABSTRACT:

Background

Infliximab (IFX) effectively treats patients with inflammatory bowel disease (IBD). IFX-biosimilar (IFX-BS) has the same amino acid sequence as that of the IFX originator, and its increasing use is expected to reduce national healthcare costs. Long-term efficacy and safety of IFX-BS in patients with Crohn's disease (CD) and ulcerative colitis (UC) have not been completely investigated.

Methods

We conducted a retrospective, multicenter observational study of patients with IBD who received IFX-BS treatment at three hospitals between October 2016 and April 2022. Clinical data were collected from electronic medical records and evaluated for achieving clinical remission (CR) using Crohn's disease activity index (CDAI) and partial Mayo (pMayo) score, persistency of long

SUBMITTER: Kazama T 

PROVIDER: S-EPMC10497130 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature